Premium
P2‐459: In‐vitro mechanisms of action of naturally occurring autoantibodies against Aβ
Author(s) -
Gold Maike,
Bach JanPhilipp,
Mengel David,
Bacher Michael,
Dodel Richard
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.1331
Subject(s) - microglia , western blot , in vitro , cytokine , autoantibody , neuroinflammation , immunology , chemistry , antibody , medicine , biochemistry , inflammation , gene
injected controls (n1⁄4 5). Interestingly, a slight lowering of ISFAßx-40 fluctuating levels in NPT001-injectedmicewas observed across days. In a subset of mice tested (n1⁄4 2), Aßx-42 levels also did not increase following NPT001 injection. Importantly, NPT001 significantly reduced Aß plaque load by 52.56 7.5% (mean6 SEM) in the injected hemisphere compared to the contralateral hemisphere in the same mice. In contrast, vehicle-injected mice had similar plaque load in the ipsilateral and contralateral hemispheres. All six mice in the NPT001-injected group had a decline in plaque load. Results indicate that ISF Aß levels, as assessed by in vivo microdialysis, did not change as a result of NPT001 injection despite a 50% reduction in Aß plaque load. Conclusions: NPT001 reduces Aß plaque load by a mechanism or pathway that doesnot involve solubilizationand/or releaseofAßmonomers intobrain ISF.